A Cure for Mantle Cell Lymphoma?

Mantle cell lymphoma (MCL), a rare disease that has been difficult to study in clinical trials, may be curable in the not-so-distant future, according to researchers from the University of Texas.

Studies conducted over the last couple of decades have provided new clues about MCL, enabling doctors and scientists to better understand the disease.

According to Dr. Michael L. Wang, professor in the Department of of Lymphoma/Myeloma at UT's MD Anderson Cancer Center in Houston, the cure may specifically have to do with the patient's age and the initial approach to treatment.

"We are within reach of curing mantle cell lymphoma within a shorter period of time, much sooner than we expected," Dr. Wang told Medscape.

Two intensive therapies

For young and fit patients, the two most effective treatments for MCL have been those that include high-dose cytarabine (HDAC) combined with chemotherapy and autologous stem cell transplantation (ASCT).

"These two intensive therapies have produced overall survival exceeding 10 years. Such overall survival has not been achieved by salvage therapies, such as R-CHOP or bendamustine," Wang said.

Young and healthy patients, Wang explained, can benefit most from primary or frontline therapies used to treat MCL.

"If you mess up with the frontline therapy, you have missed the chance for long-term remission. If you give young, fit patients salvage therapy, their disease will relapse quickly, they will get into a pattern of constant therapies, and they will die from their disease much sooner than 10 years," he said.

Wang's research found that, with proper treatment, younger MCL patients can have a higher survival rate and better quality of life.

"[MCL] used to have a median survival of 3 to 5 years," he said.

Source: Medscape
Image courtesy of Photokanok/FreeDigitalPhotos.net

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...